Ftse Mib
34.249,77
0,91%
DAX
18.161,01
1,32%
S&P 500
5.099,96
1,02%
NASDAQ Composite
15.927,90
2,03%
Bitcoin
62.991,86
-1,17%

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Assistenza
Home Investire Azioni U.S.A. NASDAQ Aeglea BioTherapeutics Inc (AGLE) Aeglea BioTherapeutics Inc (AGLE) Notizie

Aeglea BioTherapeutics Inc

AGLE
12,01
0,00 (0,00%)
26 Apr 2024 - Chiuso
Dati in Delay di 15 minuti
Borsa: NASDAQ
Tipo: Azione
Valuta: USD

Ultime notizie

Data Ora Fonte Titolo
25/4/202422:55EDGAR2Form 4 - Statement of changes in beneficial ownership of..
25/4/202422:40EDGAR2Form SC 13D/A - General statement of acquisition of..
25/4/202422:21EDGAR2Form 8-K - Current report
02/4/202422:36EDGAR2Form ARS - Annual Report to Security Holders
01/4/202422:06EDGAR2Form DEF 14A - Other definitive proxy statements
20/3/202412:14EDGAR2Form PRE 14A - Other preliminary proxy statements
18/3/202421:06EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
18/3/202413:31EDGAR2Form 8-K - Current report
14/3/202421:12EDGAR2Form POS AM - Post-Effective amendments for registration..
28/11/202322:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
28/11/202313:33EDGAR2Form 8-K - Current report
27/11/202322:36EDGAR2Form 4 - Statement of changes in beneficial ownership of..
27/11/202322:33EDGAR2Form 4 - Statement of changes in beneficial ownership of..
27/11/202322:32EDGAR2Form 3 - Initial statement of beneficial ownership of..
27/11/202322:27EDGAR2Form 3 - Initial statement of beneficial ownership of..
27/11/202322:25EDGAR2Form 4 - Statement of changes in beneficial ownership of..
27/11/202314:30PRNUSAeglea BioTherapeutics Announces Name Change to Spyre..
23/11/202302:45EDGAR2Form 8-K - Current report
22/11/202323:00PRNUSAeglea BioTherapeutics Announces Grants of Inducement Awards
15/11/202323:18EDGAR2Form S-1/A - General form for registration of securities..
15/11/202323:14EDGAR2Form 8-K - Current report
14/11/202321:13EDGAR2Form SC 13G - Statement of acquisition of beneficial..
09/11/202322:10EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
09/11/202322:06EDGAR2Form 8-K - Current report
09/11/202322:05PRNUSAeglea BioTherapeutics Reports Third Quarter 2023 Financial..
03/11/202322:00PRNUSAeglea BioTherapeutics Announces Grants of Inducement Awards
31/10/202301:00PRNUSAeglea BioTherapeutics to Participate in Upcoming November..
27/10/202303:53EDGAR2Form DEF 14A - Other definitive proxy statements
24/10/202315:00EDGAR2Form 8-K - Current report
07/10/202303:40EDGAR2Form PRER14A - Preliminary Proxy Soliciting materials
05/10/202323:13EDGAR2Form 8-K - Current report
03/10/202300:02PRNUSAeglea BioTherapeutics Announces Grants of Inducement Awards
25/9/202322:02EDGAR2Form 8-K - Current report
14/9/202323:03PRNUSAeglea BioTherapeutics to Participate in Upcoming September..
08/9/202323:05EDGAR2Form 8-K - Current report
07/9/202314:40PRNUSAeglea BioTherapeutics Announces Reverse Stock Split
05/9/202322:15EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/9/202322:10EDGAR2Form 3 - Initial statement of beneficial ownership of..
05/9/202322:10EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/9/202322:06EDGAR2Form 3 - Initial statement of beneficial ownership of..
05/9/202313:06EDGAR2Form 8-K - Current report
05/9/202313:00PRNUSAeglea BioTherapeutics Expands Executive Leadership Team..
11/8/202313:07EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
11/8/202313:02EDGAR2Form 8-K - Current report
11/8/202313:01EDGAR2Form 8-K - Current report
11/8/202313:00PRNUSAeglea BioTherapeutics Reports Second Quarter 2023 Financial..
08/8/202303:51EDGAR2Form PRE 14A - Other preliminary proxy statements
07/8/202322:25EDGAR2Form S-3 - Registration statement under Securities Act of..
28/7/202315:01EDGAR2Form SC 13G - Statement of acquisition of beneficial..
27/7/202313:01EDGAR2Form 8-K - Current report
Apertura: Min: Max:
Chiusura: 12,01

La tua Cronologia

NASDAQ
AGLE
Aeglea BioTherapeutics
Delayed Upgrade Clock

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' CLICCA QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network